隐藏我朴素的愿望
由药明合联WuXi XDC和佰傲谷BioValley共同主办的2024第三届生物偶联药全球创新峰会(Global XDC 2024),将于9月10-12日在无锡重磅回归。大会涵盖2个主论坛+4个分论坛,预计参会企业300+家,参会专家100+位,参会观众1000+人。大会以“探索偶联药的无限可能”为主题,将聚焦于新靶点发现与验证、ADC和新型偶联药物创新技术、载荷-连接子新技术,以及CMC挑战和商业化策略等内容,探索前沿技术进步、分享国际优秀生物科技公司的创新经验、引领ADC和XDC的新未来!
本届峰会邀请了众多生物偶联药领域的国际专家与会,共同探讨创新合作,碰撞思想,助力生物偶联药行业蓬勃发展。
1.国际嘉宾阵容来袭,聆听偶联药的世界声音
2.精选热门议题一览,探索偶联药的无限可能
Keynote Speech
•Rina-S-the missing link(er)
•Protein homeostasis by dual-precision targeted protein degradation and stabilization
•A novel dual-payload ADC platform to overcome payload resistance and maximize therapeutic promise of ADCs
•MYTX-011: acMET-targeting ADC engineered for anti-tumor activity against a broader spectrum ofcMETexpression
•NTX1105: development of a best-in-class ADC targeting Nectin-4
•Collaborating within the global life science ecosystem to advance breakthrough science
论坛一:Next generation ADCs: Novel targets, payloads, payload-linkers, and conjugation technologies
•Next generation ADCs: novel targets, payloads, linkers and conjugation technologies
•Nexatecan™: OHPAS-able Topo1 inhibitor for ADC
•Introduction to PINOT-ADC platform: novel Top1 inhibitor payload, tandem cleavable and super-hydrophiliclinker,and dual payload system
•Versatile drug bundle-based ADC platform: achieving site-specific conjugation, DAR of 8 or 12, and dual payloads
•CS5001, a potential best-in-class ROR1 ADC
•Discovery of AT65474, a highly selective anti-CLDN6 ADC with a proprietary payload
•Polysorbates in biopharmaceuticals-approaches to mitigate risk
论坛二:Bioconjugates development beyond ADCs
•RDC-the exploration of new drug modality in unmet clinical need
•Intra-cellular mutant epitopes-novel targets for ADC and bispecific antibodies?
•GBB’s AI-enabled ecosystem elevating biological drug development
•Developing radiopharmaceuticals targeting CLDN 18.2 with nanobodies
•Fully human common light chain technology for novel ADCs
论坛三:Innovative bioconjugate discovery: from target selection toPreClinicalCandidate (PCC)
•HarnessingAbClickPro®for AT-211: leading CLDN 18.2 ADCs with superior therapeutic index
•An overview on the new topoisomerases inhibitors technologies
•Next generationADCs:noveltargets, payloads, linkers and conjugation technologies
•Challenges and solutions for clinical PK bioanalysis of antibody drug conjugates (ADCs)
论坛四:CMC challenges and commercialization strategies
•CMC scale-up challenges and COGs for site specific ADCs
•Innovative bioassays: translate clinical effects into a rigorous system of XDC product assessment
•The integrated analytical platform enables accelerated CMC development of XDCs
•QbDconsiderations for ADC process
•HowWuXiBio’sMicrobial Platform facilitates rapid and cost-effective ADC development and manufacturing
•Non-clinical strategies for ADC drugs
3.欢迎更多XDC研发企业加入我们
主办单位:药明合联WuXi XDC、佰傲谷BioValley
大会时间:2024年9月10-12日(周二/周三/周四)
大会地点:中国·无锡君来洲际酒店
参会报名:扫码下方二维码报名
【标准通票:200元/人】
联系我们:定制参展/商务合作请联系:Stephen Sun 15966587556(微信同号)
参会报名/媒体合作请联系:Abby Jiang 18217659261(微信同号)
4.特别感谢以下单位的支持
[来源:仪器信息网] 未经授权不得转载
展会回顾 | 2024BPD第七届生物药工艺发展大会顺利闭幕
2024.08.16
2024.08.13
第三届地球与太空:从红外到太赫兹国际学术会议ESIT2024(第一轮通知)
2024.04.01
版权与免责声明:
① 凡本网注明"来源:仪器信息网"的所有作品,版权均属于仪器信息网,未经本网授权不得转载、摘编或利用其它方式使用。已获本网授权的作品,应在授权范围内使用,并注明"来源:仪器信息网"。违者本网将追究相关法律责任。
② 本网凡注明"来源:xxx(非本网)"的作品,均转载自其它媒体,转载目的在于传递更多信息,并不代表本网赞同其观点和对其真实性负责,且不承担此类作品侵权行为的直接责任及连带责任。如其他媒体、网站或个人从本网下载使用,必须保留本网注明的"稿件来源",并自负版权等法律责任。
③ 如涉及作品内容、版权等问题,请在作品发表之日起两周内与本网联系,否则视为默认仪器信息网有权转载。
谢谢您的赞赏,您的鼓励是我前进的动力~
打赏失败了~
评论成功+4积分
评论成功,积分获取达到限制
投票成功~
投票失败了~